Trials / Completed
CompletedNCT03364036
Evaluation of the Onset of Action in Highly Active MS (MAGNIFY)
A 2-year Prospective Study to Evaluate the Onset of Action of Mavenclad® in Subjects With Highly Active Relapsing Multiple Sclerosis (MAGNIFY)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 270 (actual)
- Sponsor
- Merck KGaA, Darmstadt, Germany · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study was to determine the onset of Mavenclad® action by frequent magnetic resonance imaging (MRI) assessment of the combined unique active (CUA) lesions in participants with highly active relapsing multiple sclerosis (MS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mavenclad® | Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. |
Timeline
- Start date
- 2018-05-28
- Primary completion
- 2020-05-05
- Completion
- 2022-02-21
- First posted
- 2017-12-06
- Last updated
- 2023-03-16
- Results posted
- 2021-05-27
Locations
54 sites across 14 countries: Australia, Austria, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Poland, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT03364036. Inclusion in this directory is not an endorsement.